| Original language | English (US) |
|---|---|
| Pages (from-to) | 1045-1046 |
| Number of pages | 2 |
| Journal | Pain |
| Volume | 155 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2014 |
| Externally published | Yes |
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
- Anesthesiology and Pain Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Response to letter to the Editor. / Dworkin, Robert H.; O'Connor, Alec B.; Kent, Joel; Mackey, Sean C.; Raja, Srinivasa N.; Stacey, Brett R.; Levy, Robert M.; Backonja, Miroslav; Baron, Ralf; Harke, Henning; Loeser, John D.; Treede, Rolf Detlef; Turk, Dennis C.; Wells, Christopher D.
In: Pain, Vol. 155, No. 5, 05.2014, p. 1045-1046.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Response to letter to the Editor
AU - Dworkin, Robert H.
AU - O'Connor, Alec B.
AU - Kent, Joel
AU - Mackey, Sean C.
AU - Raja, Srinivasa N.
AU - Stacey, Brett R.
AU - Levy, Robert M.
AU - Backonja, Miroslav
AU - Baron, Ralf
AU - Harke, Henning
AU - Loeser, John D.
AU - Treede, Rolf Detlef
AU - Turk, Dennis C.
AU - Wells, Christopher D.
N1 - Funding Information: R.H.D. has received, in the past 12 months, research grants from the US Food and Drug Administration and the US National Institutes of Health, and compensation for activities involving clinical trial research methods from Acorda, Anika, Avanir, Bayer, Charleston, Concert, DePuy, Flexion, Genentech, Johnson & Johnson, Lilly, Lpath, Nektar, Neura, Olatec, Omeros, PeriphaGen, Pfizer, Phosphagenics, Prolong, Q-Med, Regenesis, Sanofi, Spinifex, Takeda, Taris, and Teva; S.N.R. has received research support or consulting fees from Allergan, Alpharma, Medtronic, Pfizer, QRxPharma, and Schering-Plough; B.R.S. has received research support or consulting fees in the past year from Boston Scientific, Pfizer, and XenoPort; R.M.L. has received research support, consulting fees, or honoraria in the past year from Bioness, Codman, Medtronic Neurological, Northstar Neuroscience, St. Jude Neuromodulation, and Stryker; R.B. is a member of the Innovative Medicines Initiative Europain and has received research support, consulting fees, or honoraria from Allergan, Astellas, AstraZeneca, Bayer-Schering, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Desitin, Eisai, Genzyme, Grünenthal, Lilly, Medtronic, Mundipharma, Novartis, Pfizer, Sanofi Pasteur, Teva, and UCB Biosciences; H.H. has received research support in the past year from Astellas; J.D.L. has received consulting fees in the past year from Biodelivery Sciences, Johnson & Johnson, Medtronic, and XenoPort; R.D.T. has received research support, consulting fees, or honoraria in the past year from Astellas, AWD Pharma, Boehringer Ingelheim, Dr. Kade, GlaxoSmithKline, Grünenthal, and Pfizer; D.C.T. has received research support, consulting fees, or honoraria in the past year from Lilly, Mallinckrodt, Nektar, Orexo, Pfizer, Ortho-McNeil Janssen, and Xydnia; C.D.W. has received consulting and speakers’ fees from Astellas and Grünenthal; A.B.O., J.K., M.B., and S.C.M. have no financial disclosures to report.
PY - 2014/5
Y1 - 2014/5
UR - http://www.scopus.com/inward/record.url?scp=84898599877&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898599877&partnerID=8YFLogxK
U2 - 10.1016/j.pain.2014.01.029
DO - 10.1016/j.pain.2014.01.029
M3 - Letter
C2 - 24513276
AN - SCOPUS:84898599877
VL - 155
SP - 1045
EP - 1046
JO - Pain
JF - Pain
SN - 0304-3959
IS - 5
ER -